Spineology® Announces FDA Clearance of Rampart One™ Anterior Lumbar Interbody Fusion System

June 27, 2017

ST. PAUL, Minn.–(BUSINESS WIRE)–Spineology, Inc. the innovator in anatomy-conserving surgery™, is excited to announce FDA clearance of the Rampart One Anterior Lumbar Interbody Fusion System.

Rampart One is designed to minimize the exposure and vascular retraction requirements associated with traditional anterior spinal fusion procedures. The system includes both standard and oblique interbody device footprints each with integrated fixation screws.

Advertisement

“Minimizing exposure and retraction are cornerstone elements of all Spineology anatomy conserving designs. We are very excited about this approval and look forward to entering the anterior market in the near future,” said John Booth CEO of Spineology.

“Variable angle instrumentation and integrated guides are colinear with the access, providing the surgeon the ability to keep the incision to a minimum,” said Dr. Jeremy Shore of Boston, Massachusetts.

“For instances where there is limited to no vessel mobility, the Rampart One Oblique footprint is an excellent option,” adds Dr. Clifford Tribus of Madison, Wisconsin.

Rampart One is manufactured from Invibio® PEEK-OPTIMA® HA Enhanced material. This provides an improved osteoconductive surface for bone on-growth while preserving the traditional benefits of PEEK-OPTIMA Natural including a modulus similar to bone, reduced stress shielding and artifact-free imaging.

About Spineology Inc.

Spineology Inc. provides innovative, anatomy-conserving spinal technologies for surgeons and their patients. Spineology surgical techniques conserve spinal bone, ligament and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity and accelerating patient recovery. Learn more at spineology.com.

Contacts

Spineology Inc.
John Booth, 651-256-8511
jbooth@spineology.com
or
Risdall
Dave Folkens, 651-286-6713
dave@risdall.com

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement